World's Best Scientists 2026 revealed!
José M. Gatell

José M. Gatell

Award Badge
Microbiology
Spain
2026

D-Index & Metrics

Microbiology

D-Index
98
Citations
41092
World Ranking
451
National Ranking
9

Medicine

D-Index
98
Citations
42661
World Ranking
8825
National Ranking
126

José M. Gatell publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where José M. Gatell sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 265 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 234 scientists 205–214 publications: 208 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 533 publications — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

José M. Gatell D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where José M. Gatell sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 112 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 123 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 94 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 98 D-Index — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Microbiology in Spain Leader Award
  • 2025 - Research.com Microbiology in Spain Leader Award

Overview

José M. Gatell is affiliated with the University of Barcelona in Spain. Their research primarily focuses on fields within medicine, particularly immunology and microbiology, with a significant emphasis on infectious diseases. They have contributed extensively to the study of HIV/AIDS, including drug development, treatment, and related health complications.

Their research topics include:

  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • HIV-related health complications and treatments
  • HIV/AIDS Research and Interventions
  • Pharmacological Effects and Toxicity Studies
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Immune Cell Function and Interaction

José M. Gatell has published papers across a variety of journals and venues. Frequent publication venues include:

  • UNC Libraries
  • Journal of Antimicrobial Chemotherapy
  • The Lancet HIV
  • Clinical Infectious Diseases
  • AIDS Research and Human Retroviruses

Notable recent papers authored or co-authored by José M. Gatell include:

  • Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the International AIDS Society-USA Panel, 2020, UNC Libraries
  • Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial, 2021, The Lancet HIV
  • Immunological and virological findings in a patient with exceptional post-treatment control: a case report, 2022, The Lancet HIV
  • Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial, 2023, Clinical Infectious Diseases
  • Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease, 2020, Journal of Antimicrobial Chemotherapy

Throughout their career, José M. Gatell has frequently collaborated with several co-authors. These include:

  • Peré Domingo
  • Bonaventura Clotet
  • Estebán Martínez
  • Christoph Stephan
  • Elisa de Lazzari

Their work spans numerous subfields in medicine such as infectious diseases, virology, emergency medicine, pediatrics, perinatology and child health, and epidemiology, reflecting a broad scope of study within clinical and therapeutic contexts.

Best Publications

  • Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F Gunthard;Judith A Aberg;Joseph J Eron;Jennifer Frances Hoy

  • Treatment for adult HIV infection : 2006 recommendations of the international AIDS society-USA panel

    Scott M. Hammer;Michael S. Saag;Mauro Schechter;Julio S. G. Montaner

  • Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel

    Patrick G. Yeni;Scott M. Hammer;Charles C. J. Carpenter;David A. Cooper

  • Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

    Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron

  • Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

    Graeme J. Moyle;Brian G. Gazzard;David A. Cooper;José Gatell

  • Antiretroviral Treatment of Adult HIV Infection

    Scott M. Hammer;Joseph J. Eron;Peter Reiss;Robert T. Schooley

  • Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

    Patrick G. Yeni;Scott M. Hammer;Martin S. Hirsch;Michael S. Saag

  • Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

    Beatriz Grinsztejn;Bach Yen Nguyen;Christine Katlama;Jose M. Gatell

  • Re-intubation increases the risk of nosocomial pneumonia in patients needing mechanical ventilation.

    A Torres;J M Gatell;E Aznar;M el-Ebiary

  • HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

    Maria J Buzón;Marta Massanella;Josep M Llibre;Anna Esteve

  • Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

    David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh

  • Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study

    Sean Emery;Jacqueline A. Neuhaus;Andrew N. Phillips;Abdel Babiker

  • Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

    Esteban Martínez;Amanda Mocroft;Miguel A García-Viejo;José B Pérez-Cuevas

  • Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.

    Amanda Mocroft;Ole Kirk;Peter Reiss;Stephane De Wit

  • Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

    François Raffi;Hans Jaeger;Eugenia Quiros-Roldan;Helmut Albrecht

  • Beyond viral suppression of HIV – the new quality of life frontier

    Jeffrey V. Lazarus;Jeffrey V. Lazarus;Kelly Safreed-Harmon;Simon E. Barton;Dominique Costagliola

  • Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

    Esteban Martinez;José L. Blanco;Juan A. Arnaiz;José B. Perez-Cuevas

  • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    Unknown

  • Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

    Kathleen Squires;Adriano Lazzarin;José M. Gatell;William G. Powderly

  • Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.

    Esteban Martínez;Juan A. Arnaiz;Daniel Podzamczer;David Dalmau

  • Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

    Joseph J. Eron;Bonaventura Clotet;Jacques Durant;Christine Katlama

Frequent Co-Authors

Felipe García
Felipe García University of Barcelona
José M. Miró
José M. Miró University of Barcelona
Jens D. Lundgren
Jens D. Lundgren Rigshospitalet
Josep Mallolas
Josep Mallolas University of Barcelona
Tomás Pumarola
Tomás Pumarola Vall d'Hebron Institut de Recerca
Amanda Mocroft
Amanda Mocroft University College London
Pere Domingo
Pere Domingo Autonomous University of Barcelona
Peter Reiss
Peter Reiss University of Amsterdam
Andrew N. Phillips
Andrew N. Phillips University College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees related to microbiology can open doors to diverse career paths in health and science fields. For instance, becoming a certified child life specialist offers rewarding opportunities supporting children through medical experiences. Understanding a certified child life specialist salary can help students gauge the financial benefits alongside their passion for care.

Many students face unique challenges when pursuing education, including those with legal histories. Fortunately, several degrees felons can get provide a pathway to meaningful careers, demonstrating that academic advancement remains accessible and achievable.

The healthcare sector also offers specialized roles like the functional medicine nurse practitioner, blending traditional and holistic practices. Learning about the functional medicine nurse salary helps prospective students assess financial prospects in this growing field.

For those interested in medical administration, pursuing certification as a professional coder is another viable career route. Information regarding the certified professional coder salary highlights earning potential and job stability within healthcare coding and billing.

Best Scientists Citing José M. Gatell

Trending Scientists

Recently Published Articles